Anzeige
Mehr »
Login
Freitag, 26.02.2021 Börsentäglich über 12.000 News von 656 internationalen Medien
Adhoc-Meldung: Eine ganz große Überraschung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0MU8Y ISIN: ES0157097017 Ticker-Symbol: E2Z 
Stuttgart
26.02.21
08:03 Uhr
10,820 Euro
-0,170
-1,55 %
Branche
Pharma
Aktienmarkt
IBEX-35
1-Jahres-Chart
ALMIRALL SA Chart 1 Jahr
5-Tage-Chart
ALMIRALL SA 5-Tage-Chart
RealtimeGeldBriefZeit
10,93011,16008:45
10,97011,16008:45

Aktuelle News zur ALMIRALL Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiAlmirall bags EU rights to topical psoriasis drug from MC22
ALMIRALL Aktie jetzt für 0€ handeln
MoAlmirall SA (LBTSF) on Q4 2020 Results - Earnings Call Transcript1
MoAlmirall, S.A. reports FY results2
MoUPDATE 1-Almirall's 2020 net profit falls 30%, pandemic impact to continue2
MoAlmirall's 2020 Full-Year Results123Almirall delivers on latest 2020 guidance and sets growth targets for 2021 BARCELONA, Spain, Feb. 22, 2021 /PRNewswire/ -- The company delivered on its latest guidance despite...
► Artikel lesen
MoAlmirall's 2020 net profit falls 30% due to coronavirus, generics-
MoALMIRALL, S.A.: Presentation FY2020 Financial Results4
MoALMIRALL, S.A.: A webcast with analysts and institutional investors FY 20201
17.02.Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for European Rights to Wynzora Cream for treatment of Plaque Psoriasis166In this collaboration Almirall will commercialize Wynzora Cream for treatment of plaque psoriasis in Europe and MC2 Therapeutics will be responsible for manufacturing and supply. MC2 Therapeutics...
► Artikel lesen
17.02.Almirall and MC2 Therapeutics enter a license, collaboration and commercialization agreement for European rights to Wynzora Cream for treatment of plaque psoriasis169-- In this collaboration Almirall will commercialize Wynzora Cream for treatment of plaque psoriasis in Europe and MC2 Therapeutics will be responsible for manufacturing and supply --...
► Artikel lesen
17.02.DGAP-News: MC2 Therapeutics: Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for European Rights to Wynzora(R) Cream for treatment of Plaque Psoriasis119DGAP-News: MC2 Therapeutics / Key word(s): Agreement/Market launch MC2 Therapeutics: Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for European...
► Artikel lesen
17.02.Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for European Rights to Wynzora Cream for treatment of Plaque Psoriasis161In this collaboration Almirall will commercialize Wynzora Cream for treatment of plaque psoriasis in Europe and MC2 Therapeutics will be responsible for manufacturing and supply. MC2 Therapeutics...
► Artikel lesen
17.02.ALMIRALL, S.A.: Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for European Rights to Wynzora Cream for treatment of Plaque Psoriasis-
16.02.Almirall gibt Veröffentlichung im British Journal of Dermatology über ILUMETRI (Tildrakizumab) als erste Anti-IL-23p19- Therapie, für die Daten zur 5-Jahres- Wirksamkeit und -Sicherheit aus zwei Phase-III-Studien vorliegen, bekannt224Barcelona, Spanien (ots/PRNewswire) - Das British Journal of Dermatology veröffentlichte Studienergebnisse für die anhaltende Wirksamkeit bei Patienten, die auf Tildrakizumab ansprachen sowie...
► Artikel lesen
11.02.Almirall announces New England Journal of Medicine publication of Phase III data demonstrating efficacy and safety of Klisyri (tirbanibulin)253- Klisyri (tirbanibulin) is a novel microtubule inhibitor, recently approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of actinic keratosis (AK) of the face...
► Artikel lesen
09.02.Almirall announces a new publication in the British Journal of Dermatology of ILUMETRI? (tildrakizumab) as the first anti-IL23p19 treatment for which 5-year efficacy and safety data are reported from two phase 3 studies237- The British Journal of Dermatology has published evidence of sustained efficacy in tildrakizumab responders and a favourable long-term safety profile with total tildrakizumab exposure of...
► Artikel lesen
03.02.Almirall ernennt Gianfranco Nazzi zum neuen CEO246Barcelona, Spanien (ots/PRNewswire) - - Gianfranco Nazzi bringt umfassende internationale Erfahrungen aus einer herausragenden Karriere in der Pharmaindustrie mit - Herr Nazzi wird zum 1. Mai 2021 Chief...
► Artikel lesen
03.02.Almirall announces Gianfranco Nazzi as new CEO233- Gianfranco Nazzi brings broad international experience from a distinguished career in Pharma - Mr. Nazzi will join Almirall as Chief Executive Officer on May 1, 2021 BARCELONA...
► Artikel lesen
03.02.ALMIRALL, S.A.: Almirall announces Gianfranco Nazzi as new CEO1
29.01.Almirall enlists Happify to boost psoriasis patients' mental health with digital therapeutics-
Seite:  Weiter >>
52 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1